SAB BIOTHERAPEUTICS, INC.

Company

SAB Biotherapeutics, Inc.

Filed

February 14, 2024

Accession Number

0000902664-24-001535

A Schedule 13G is filed when a passive investor acquires more than 5% of a company's shares without intent to influence control. Learn more about SC 13G filings →